Avalo Therapeutics Inc (AVTX)

Currency in USD
6.875
-0.575(-7.72%)
Real-time Data·
Advertisement
Trading near 52-week Low
Earnings results expected in 0 days
AVTX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.7387.500
52 wk Range
6.73824.270
Key Statistics
Prev. Close
7.45
Open
7.23
Day's Range
6.738-7.5
52 wk Range
6.738-24.27
Volume
783.61K
Average Volume (3m)
1.33M
1-Year Change
-61.635%
Book Value / Share
8.54
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
AVTX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
41.182
Upside
+499.01%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period

Avalo Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

14 Buy
0 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 41.182
(+499.01% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Hold---Downgrade23/10/2026
Guggenheim
Hold---Downgrade23/10/2026
H.C. Wainwright
Buy30.00+336.05%-Maintain16/10/2026
Cantor Fitzgerald
Buy---Maintain16/09/2026
Guggenheim
Buy48.00+597.67%50.00Maintain06/08/2026

Earnings

Latest Release
06/08/2026
EPS / Forecast
-0.83 / -0.58
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

Compare AVTX to Peers and Sector

Metrics to compare
AVTX
Peers
Sector
Relationship
P/E Ratio
−3.7x−1.9x−0.3x
PEG Ratio
−0.09−0.070.00
Price/Book
0.8x2.8x2.6x
Price / LTM Sales
6,308.3x56.7x2.9x
Upside (Analyst Target)
-309.9%64.3%
Fair Value Upside
Unlock14.6%9.2%Unlock

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
17.14M31.96%210.16M
Other Institutional Investors
73.49M68.04%900.99M
Public Companies & Retail Investors
0.000.00%0.00
Total
90.63M100.00%1.11B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC10.70%5,737,96670,347
BlackRock, Inc.8.14%4,365,55353,522

People Also Watch

0.420
EYPT
-1.89%
21.99
VRDN
-3.64%
28.50
CLDX
-1.62%
0.487
KPTI
-10.88%

FAQ

What Is the Avalo Therapeutics (NASDAQ: AVTX) Share Price Today?

The Avalo Therapeutics stock price today is 6.875 USD.

What Stock Exchange Does Avalo Therapeutics (AVTX) Trade On?

Avalo Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Avalo Therapeutics?

The stock symbol (also called a 'ticker') for Avalo Therapeutics is "AVTX."

What Is the Current Avalo Therapeutics Market Capitalisation?

As of today, Avalo Therapeutics (NASDAQ: AVTX) market cap is 368.970M USD.

What Is Avalo Therapeutics's (AVTX) Earnings Per Share (TTM)?

The Avalo Therapeutics EPS is currently -4.18 (Trailing Twelve Months).

When Is the Next Avalo Therapeutics Earnings Date?

Avalo Therapeutics's next earnings report will be released on 05/11/2026.

Is AVTX a Buy or Sell From a Technical Analyst Perspective?

Based on today's Avalo Therapeutics moving averages and other technical indicators, the daily buy/sell signal for AVTX stock is Strong Sell.

How Many Times Has Avalo Therapeutics Stock Split?

Avalo Therapeutics has split 2 times. (See the AVTX stock split history page for full effective split date and price information.)

How Many Employees Does Avalo Therapeutics Have?

Avalo Therapeutics has 33 employees, based on their latest Companies House report.

What is the current trading status of Avalo Therapeutics (NASDAQ: AVTX)?

As of 23/10/2026, Avalo Therapeutics (AVTX) is trading at a share price of 6.875 USD, with a previous close of 7.450 USD. The stock has fluctuated within a day range of 6.738 USD to 7.500 USD, while its 52-week range spans from 6.738 USD to 24.270 USD.

What Is Avalo Therapeutics (AVTX) Price Target According to Analysts?

The average 12-month price target for Avalo Therapeutics is 41.182 USD, with a high estimate of 60 USD and a low estimate of 22 USD. 14 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +499.01% Upside potential.

What Is the AVTX Premarket Price?

AVTX's last pre-market stock price is 7.200 USD. The pre-market share volume is 23,140.000, and the stock has decreased by -0.250, or -3.360%.

What Is the AVTX After Hours Price?

AVTX's last after hours stock price is 7.520 USD, the stock has decreased by 0.070, or 0.940%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.